Related Experiment Video
Updated: Jun 14, 2026
05:49
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
Proteomics in antiphospholipid syndrome: a review
M J Cuadrado1, M A Aguirre, N Barbarroja
1Lupus Research Unit, St Thomas' Hospital, London, UK. mjcuadrado@yahoo.com
Lupus
|April 1, 2010
Summary
Antiphospholipid antibodies (aPL) are linked to thrombosis and pregnancy issues, but predicting outcomes is difficult. Proteomics may offer new biomarkers to identify patient subgroups and improve management for antiphospholipid syndrome (APS).
Area of Science:
- Immunology
- Proteomics
- Genomics
Background:
- Antiphospholipid antibodies (aPL) are associated with thrombosis and pregnancy complications.
- Pathogenic mechanisms for thrombosis and pregnancy morbidity in aPL-positive patients remain unclear.
- Lack of reliable biomarkers hinders prognosis prediction for patients with aPL.
Purpose of the Study:
- To review recent studies using genomics and proteomics to understand antiphospholipid syndrome (APS) pathogenesis.
- To explore the potential of novel biomarkers for predicting prognosis in APS patients.
Main Methods:
- Review of recent scientific literature focusing on proteomic and genomic approaches.
- Analysis of studies investigating protein and peptide alterations in APS.
Main Results:
- Proteomics and genomics offer promising avenues for discovering biomarkers in APS.
- Current proteomic efforts have yielded few qualified biomarkers for APS.
Conclusions:
- Genomic and proteomic techniques are crucial for elucidating APS pathogenic mechanisms.
- Future biomarker discovery through these techniques may enable personalized management and improved prognosis for diverse APS patient subgroups.
